1. Show article details.

    Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results

    Business Wire – 7:00 AM ET 03/13/2015

    Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results for the three-month period and year ended December 31, 2014.

  2. Show article details.

    Four Oncology Key Opinion Leaders to Present at Spectrum Pharmaceuticals’ Analyst Day on Friday, March 13th

    Business Wire – 7:00 AM ET 03/11/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, will be hosting its fourth quarter 2014 financial results and analyst day in New York City on Friday, March 13, 2015 from 10:00 a.m. to 12:00 p.m. ET.

  3. Show article details.

    Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan

    Business Wire – 7:00 AM ET 03/09/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its New Drug Application for Captisol-Enabled Melphalan, has been accepted by the U.S. Food and Drug Administration.

  4. Show article details.

    Spectrum Pharmaceuticals In-Licenses Poziotinib, a Novel pan-HER Inhibitor With Clinical Activity in Several Solid Tumors, From Hanmi Pharmaceuticals

    Business Wire – 7:00 AM ET 03/04/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it has entered into a licensing agreement with Hanmi Pharmaceuticals for poziotinib, a drug being investigated for the treatment of cancer.

  5. Show article details.

    Spectrum Pharmaceuticals to Present Corporate Update at the 2015 RBC Capital Markets' Global Healthcare Conference on February 24th

    Business Wire – 7:00 AM ET 02/20/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the 2015 RBC Capital Markets' Global Healthcare Conference being held at The New York Palace Hotel in ...

  6. Show article details.

    Spectrum Pharmaceuticals Announces Fourth Quarter 2014 Financial Results and Analyst Day

    Business Wire – 7:00 AM ET 02/17/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will be hosting its fourth quarter 2014 financial results and analyst day in New York City on Friday, March 13, 2015 from 10:00 a.m. to 12:00 p.m. Spectrum speakers scheduled to present include: External key opinio...

  7. Show article details.

    Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan at the 2015 BMT Tandem Meeting

    Business Wire – 7:00 AM ET 02/12/2015

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced results of a clinical study of Propylene Glycol-Free, Captisol-enabled Melphalan Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma.

  8. Show article details.

    Technical Scrutiny on Biotech Stocks - Galena Biopharma, Synta Pharma, Merrimack Pharma, Vertex Pharma, and Spectrum Pharma

    PR Newswire – 8:55 AM ET 01/07/2015

    LONDON, January 7, 2015 Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (GALE), Synta Pharmaceuticals Corporation (SNTA), Merrimack Pharmaceuticals Inc. (MACK), Vertex Pharmaceuticals Inc. (VRTX), and Spectrum Pharmaceuticals Inc. (SPPI). Free research on these five companies can be accessed at: http://investor-edge.com/register.

Page:

Today's and Upcoming Events

  • May
    7

    SPPI to announce Q1 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Mar
    13

    SPPI Earnings Conference Call at 10:00 AM Listen

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.